Needham & Company Reiterates Buy Rating, $6 Price Target on Avadel Pharmaceuticals (AVDL), Sees $300M Opportunity for FT218 in Narcolepsy
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $6.00 price target on Avadel Pharmaceuticals (NASDAQ: AVDL), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
